JPWO2020231977A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020231977A5
JPWO2020231977A5 JP2021568200A JP2021568200A JPWO2020231977A5 JP WO2020231977 A5 JPWO2020231977 A5 JP WO2020231977A5 JP 2021568200 A JP2021568200 A JP 2021568200A JP 2021568200 A JP2021568200 A JP 2021568200A JP WO2020231977 A5 JPWO2020231977 A5 JP WO2020231977A5
Authority
JP
Japan
Prior art keywords
pyridazin
pyridin
fluoro
oxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533120A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032446 external-priority patent/WO2020231977A1/en
Publication of JP2022533120A publication Critical patent/JP2022533120A/ja
Publication of JPWO2020231977A5 publication Critical patent/JPWO2020231977A5/ja
Pending legal-status Critical Current

Links

JP2021568200A 2019-05-13 2020-05-12 ハンチントン病を処置するための化合物 Pending JP2022533120A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846896P 2019-05-13 2019-05-13
US62/846,896 2019-05-13
PCT/US2020/032446 WO2020231977A1 (en) 2019-05-13 2020-05-12 Compounds for treating huntington's disease

Publications (2)

Publication Number Publication Date
JP2022533120A JP2022533120A (ja) 2022-07-21
JPWO2020231977A5 true JPWO2020231977A5 (sr) 2023-05-16

Family

ID=70919171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568200A Pending JP2022533120A (ja) 2019-05-13 2020-05-12 ハンチントン病を処置するための化合物

Country Status (12)

Country Link
US (1) US20220204478A1 (sr)
EP (2) EP4219466A1 (sr)
JP (1) JP2022533120A (sr)
KR (1) KR20220022114A (sr)
CN (1) CN114245794A (sr)
AU (1) AU2020277027A1 (sr)
BR (1) BR112021022624A2 (sr)
CA (1) CA3139821A1 (sr)
IL (1) IL287945A (sr)
MX (1) MX2021013854A (sr)
SG (1) SG11202112504YA (sr)
WO (1) WO2020231977A1 (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281633B (en) 2015-12-10 2022-07-01 Ptc Therapeutics Inc Methods for treating Huntington's disease
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
JP2021506978A (ja) 2017-12-22 2021-02-22 ラヴェンナ ファーマシューティカルズ，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
EA202092896A1 (ru) 2018-06-27 2021-04-13 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4132923A1 (en) * 2020-04-09 2023-02-15 PTC Therapeutics, Inc. Compounds for treating huntington's disease
AR122072A1 (es) 2020-05-13 2022-08-10 Chdi Foundation Inc Moduladores htt para tratar la enfermedad de huntington
KR20240069714A (ko) 2021-08-25 2024-05-20 피티씨 테라퓨틱스, 인크. Nlrp3 억제제
WO2023034827A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202327604A (zh) * 2022-01-07 2023-07-16 大陸商藥捷安康(南京)科技股份有限公司 Ｎｌｒｐ３發炎小體抑制劑及其應用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447075B2 (en) * 2011-08-02 2016-09-20 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as EAAT2 activators
MY174339A (en) * 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
IL281633B (en) * 2015-12-10 2022-07-01 Ptc Therapeutics Inc Methods for treating Huntington's disease
EA202092896A1 (ru) * 2018-06-27 2021-04-13 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероциклические и гетероарильные соединения для лечения болезни гентингтона

Similar Documents

Publication Publication Date Title
US20230234958A1 (en) Shp2 phosphatase inhibitors and methods of use thereof
US11420958B2 (en) Aryl and heteroaryl substituted indole compounds
JPWO2020005873A5 (sr)
JP2018522046A5 (sr)
US10988459B2 (en) Bicyclic lactams and methods of use thereof
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JPWO2019191092A5 (sr)
JPWO2020231977A5 (sr)
US11299501B2 (en) Diazaindole compounds
JPWO2019191229A5 (sr)
JPWO2020005877A5 (sr)
JP2014521711A5 (sr)
JP2016525092A5 (sr)
US20220204478A1 (en) Compounds for treating huntington's disease
WO2018053189A2 (en) Syk inhibitors
US10214537B2 (en) Bicyclic heteroaryl amine compounds
HUE032770T2 (en) New NK-3 receptor selective antagonist compounds, pharmaceutical compositions and methods for use in NK-3 receptor mediated disorders
JP2013523884A5 (sr)
JP2011511034A5 (sr)
JP2017518326A5 (sr)
RU2013136778A (ru) Ингибиторы гистондезацетилазы, композиции и способы их применения
RU2008145504A (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
JP2020526549A5 (sr)
JPWO2022173033A5 (sr)
US20230085472A1 (en) COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS